EZH2 and myeloid leukemia: Disease-related heterozygous point mutations within the SET-domain of EZH2 mainly found in lymphomas and myeloid leukemias, alter the substrate specificity of EZH2 to generate different methylation states of H3K27 which promote oncogenic progression.